IFNA1 and COVID-19: While recent studies have shown enhanced susceptibility of IFNAR−/− K18-hACE2 mice upon SARS-CoV-2 infection (105, 106), the results of our anti-IFNAR mAb treatment studies closely mimic the anti-IFN autoantibody response in patients with severe COVID-19 (59, 60, 62, 64, 65, 67, 69, –, 71, 73).